Nexium I.V. (Esomeprazole Sodium)

Nexium I.V. (esomeprazole) is used to manage conditions related to excess gastric acid production across several acid‑related disease states.

• Gastroesophageal reflux disease (GERD): reduces acid exposure and promotes healing of esophageal irritation.
• Erosive esophagitis: facilitates mucosal healing by decreasing gastric acid secretion.
• Prevention of stress‑related mucosal bleeding: lowers risk of gastrointestinal bleeding in critically ill patients.
• Acid‑related disorders (general): provides symptomatic relief by reducing gastric acidity.

• Esomeprazole sodium selectively and irreversibly binds to the gastric H⁺/K⁺‑ATPase enzyme (the proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces basal and stimulated gastric acid secretion, leading to increased gastric pH.

Adverse reactions reported with intravenous esomeprazole include both common and less frequent events.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools occurring during treatment.
• Nausea: transient feeling of queasiness.
• Injection site reactions: erythema or discomfort at the infusion site.
• Abdominal pain: mild discomfort in the stomach region.
• Dyspepsia: indigestion or upper abdominal fullness.

Serious or Rare Side Effects

• Severe hypersensitivity: anaphylaxis, angioedema, or urticaria.
• Clostridioides difficile infection: possible severe colitis.
• Serum magnesium deficiency: prolonged therapy may lead to low magnesium levels.
• Liver enzyme elevation: possible hepatotoxicity requiring monitoring.
• Severe thrombocytopenia: rare drop in platelet count.

When using Nexium I.V., clinicians should consider several precautionary measures to ensure safe administration.

• Assess renal function: dose adjustment may be required in severe impairment.
• Monitor electrolyte levels: especially magnesium and potassium during prolonged therapy.
• Use with caution in hepatic impairment: limited data, monitor liver enzymes.
• Avoid in known hypersensitivity to esomeprazole or other PPIs.
• Evaluate pregnancy risk: safety category unknown; weigh benefits versus potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Esomeprazole may affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased absorption and efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation.
• Digoxin: increased serum levels, monitor for toxicity.
• Methotrexate (high dose): reduced renal clearance, monitor levels.